Roundup Settlement Approved: Judge Boyer Signs Off on $7.25 Billion Deal With $600 Million in Fees
The Roundup settlement was approved on Nov. 20, 2026, when St. Louis Judge Timothy Boyer granted final approval to Monsanto's $7.25 billion class deal for current and future non-Hodgkin lymphoma claims. Fees came in at $600 million, and an objector appeal now controls when money moves.
Torts Desk··13 min read

Roundup settlement approved: what Judge Boyer ordered on November 20
The Roundup settlement was approved on Friday, Nov. 20, 2026, when Judge Timothy Boyer of the Circuit Court of the City of St. Louis entered a written judgment granting final approval to King v. Monsanto Co., Monsanto's class settlement that pays up to $7.25 billion over roughly two decades to people who developed, or later develop, non-Hodgkin lymphoma after Roundup exposure. The order binds an estimated 65,000 pending claimants and a nationwide futures subclass, awards $600 million in attorneys' fees, and is now subject to appeal, which will decide how soon any claimant is actually paid.
With the Roundup settlement approved, the ruling ends a two-month wait that began when Boyer reserved decision at the Sept. 14 fairness hearing and that Bayer's chief executive had publicly predicted would end "before Christmas." It is a rare final approval of a futures-inclusive mass tort class settlement for a product that remains on the market, and it was entered by a state trial court rather than by the federal Multidistrict Litigation (MDL) judge who has supervised Roundup litigation since 2016.
Three findings in the judgment, as reported by the Associated Press and St. Louis Public Radio, frame everything that follows. Boyer called the average individual payouts "fair and adequate." He described the total dollar commitment as "among the largest in the history of mass tort personal-injury class action settlements." And he found a real risk that Bayer would have sought bankruptcy protection if he had rejected the deal, a finding that weighs directly on the Superiority and adequacy analysis an appellate court will review.
Who approved the $7.25 billion Roundup settlement, and when?
Judge Timothy Boyer, a circuit judge of Missouri's 22nd Judicial Circuit (the City of St. Louis), signed the final approval order on Nov. 20, 2026. He had granted preliminary approval on March 4, 2026, directed class notice, closed the opt-out and objection window on June 4, 2026, and heard objectors and the settling parties at the Sept. 14 fairness hearing before taking the matter under submission.
Two details in early coverage deserve correction. Bloomberg's headline described Boyer as a "US judge"; he is a Missouri state judge, and the case is not in federal court. And the approval does not come from Judge Vince Chhabria, who presides over the federal Roundup MDL, No. 2741, in the Northern District of California and who criticized the deal from the bench in April 2026. The federal court has no role in approving this settlement.
Roundup settlement approved after nine months: the timeline
| Date | Event |
|---|---|
| Feb. 17, 2026 | Monsanto announces the class settlement; King v. Monsanto Co. filed in the Circuit Court of the City of St. Louis |
| March 4, 2026 | Judge Boyer grants preliminary approval and orders class notice |
| June 4, 2026 | Opt-out and objection deadline closes |
| June 25, 2026 | Supreme Court decides Monsanto Co. v. Durnell, 7-2, holding FIFRA preempts label-based failure-to-warn claims |
| Aug. 2026 | Hearing moved from Aug. 19 to Sept. 14 to process opt-out revocation requests and validity disputes |
| Sept. 14, 2026 | Final approval hearing; decision reserved |
| Nov. 3, 2026 | Bayer CEO Bill Anderson says approval "could be any week now" |
| Nov. 16, 2026 | Judge Chhabria hears Monsanto's first post-Durnell dismissal motions in MDL 2741 |
| Nov. 20, 2026 | Judge Boyer grants final approval, including $600 million in fees |
Why did the judge approve the Roundup settlement?
Boyer approved the Roundup settlement because he concluded the payouts were fair and adequate when measured against what class members could realistically win by litigating, and because rejection carried a material risk of a Bayer bankruptcy filing that could have left claimants with less. That is the short answer, and each half of it maps onto a contested legal question.
The first half is a comparison with the litigation alternative, and that alternative changed sharply during the approval process. On June 25, 2026, the Supreme Court held in Monsanto Co. v. Durnell that the Federal Insecticide, Fungicide, and Rodenticide Act preempts state Failure to Warn claims that would require a cancer warning different from the EPA-approved label. Because label-based warning theories carried most Roundup cases, Durnell lowered the expected value of opting out and litigating. A settlement that objectors called thin in February looked different to a trial court in November, after a unanimous St. Louis County jury had also returned a defense verdict for Monsanto in the first post-Durnell Roundup trial on Oct. 29.
The second half, the bankruptcy finding, does work that a generous matrix alone could not. It supplies a reason why a binding class resolution is superior to tens of thousands of individual suits: if the alternative is a Chapter 11 filing, the realistic comparison is not a jury verdict but a bankruptcy distribution, delayed by years and potentially routed through a trust. Objectors will argue on appeal that a defendant's solvency risk cannot cure a structural conflict in representation; class counsel will argue it is exactly the kind of real-world risk Missouri Rule 52.08, which tracks federal Rule 23, permits a court to weigh.
Bayer, which continues to deny that Roundup or glyphosate causes cancer, had already reserved $16 billion for Roundup legal costs before this deal, according to St. Louis Public Radio. Its U.S. litigation chief said the ruling "should send a strong signal" that future plaintiffs will face significant challenges pursuing Roundup cancer claims, as quoted by the Associated Press.
Does the Roundup settlement cover future cancer cases?
Yes. The approved settlement covers both people already diagnosed with non-Hodgkin lymphoma and people exposed to Roundup in the United States before Feb. 17, 2026 who have not yet been diagnosed. That second group, the futures subclass, cannot claim money until a diagnosis arrives, but it is now bound: members who did not opt out by June 4, 2026 have exchanged the right to sue later for the right to claim a matrix payment if diagnosed within the settlement's roughly sixteen-year claims window, according to the settlement's published terms.
This is the feature that distinguishes the Roundup settlement from Bayer's 2020 program, which resolved about 100,000 existing claims but could not close the tail; a separate $1.25 billion futures arrangement was rejected by Judge Chhabria in 2021. It is also the feature that objectors attacked hardest. Attorney Gerson Smoger told the court at the September hearing that "this settlement is the scariest, worst future settlement that's ever been contemplated," arguing that it locks future claimants into a payment schedule for decades with no chance at Punitive Damages while the product stays on shelves. Critics quoted by Reuters said the structure is designed to trap current and future claimants who would rather go to court.
How much will I get from the Roundup settlement?
Individual Roundup settlement payments range from about $10,000 to $165,000, depending on which of nine tiers a claimant falls into. Tiers are set by three variables: exposure type (occupational or residential), age at diagnosis, and whether the lymphoma is an aggressive or a slower-growing subtype. The Claims Administrator is BrownGreer PLC.
| Category | Reported payment range |
|---|---|
| Overall range | About $10,000 to $165,000 |
| Occupational exposure (more than 80 hours in a job providing over half of income) | About $60,000 to $165,000 |
| Residential exposure (average) | About $20,000 to $40,000 |
| Residential quick-pay option | About $7,700 to $14,500 |
| "Special circumstances" pool | More than $400 million set aside for additional compensation |
| Security fund | $1 billion against funding shortfalls |
| Headline cap | Up to $7.25 billion, paid in capped annual installments over roughly two decades |
The ranges above come from the settlement's published matrix as summarized by FOX Television Stations and from the approval coverage; the matrix assigns points, and the final number for any individual depends on documentation of exposure and diagnosis. The headline $7.25 billion is a ceiling, not a lump sum. Monsanto funds the program through declining annual payments, so the present value of the promise is lower than the nominal figure, and the amount paid in any given year is capped. The $1 billion security fund exists to protect claimants if Monsanto cannot meet those annual obligations.
How much do the lawyers get from the Roundup settlement?
The approved Roundup settlement includes $600 million in attorneys' fees, according to the Associated Press and St. Louis Public Radio. That is about 8.3 percent of the $7.25 billion maximum and roughly $75 million less than the $675 million (about 9.3 percent) that class counsel had requested before the fairness hearing, as this site reported in September. The fee is paid from within the settlement rather than on top of it.
By ordinary Common Fund Doctrine standards, a single-digit percentage is modest; megafund awards routinely fall well below the 25 percent benchmark. The more important feature is timing. Fees fixed against a headline maximum that is paid over two decades represent a larger share of the settlement's present value than the nominal percentage suggests. Reporting so far does not say whether Boyer staged the fee or tied any portion to future payments, which is a point practitioners will want to confirm in the order itself. Individual claimants represented by their own counsel also owe that counsel whatever their Contingency Fee agreement provides, subject to any caps in the settlement terms.
When will Roundup settlement payments start?
Not immediately. Under the settlement's published terms, already-diagnosed class members have a registration window that runs after final approval, and the deadline to submit claims runs 180 days from the date any appeals are resolved. If no one appeals, the approval order becomes final and the administrator can begin processing and paying; if an objector appeals, payment of most claims waits for the appellate courts.
Missouri procedure supplies the likely calendar. Under Missouri Supreme Court Rule 81.05, a trial court judgment generally becomes final 30 days after entry if no authorized after-trial motion is filed, and Rule 81.04 then gives a party 10 days to file a notice of appeal. An appeal from the City of St. Louis goes to the Missouri Court of Appeals, Eastern District, with possible transfer to the Supreme Court of Missouri. On that schedule, the earliest realistic date for the order to be final and unappealed is late December 2026, and a contested appeal would push first payments into 2027 or later.
Can the Roundup settlement approval be appealed?
Yes. Class members who properly objected can appeal Boyer's final approval order, and the Associated Press reported that the approval could be appealed. More than 100 class members and about a dozen health care plans objected before the September hearing, and objector counsel has signaled throughout that the futures subclass would be challenged on appeal.
The core appellate question is the one the U.S. Supreme Court answered for asbestos in Amchem Products, Inc. v. Windsor (1997) and Ortiz v. Fibreboard Corp. (1999): whether a single settlement can bind both presently injured claimants and exposure-only claimants when their interests in a finite fund diverge. Those decisions interpreted federal Rule 23, which does not bind a Missouri court, but Missouri courts treat federal class-action precedent as persuasive under Rule 52.08. Objectors will press Adequacy of Representation and Class Notice to people who do not know they are class members; class counsel and Monsanto will point to separate subclass treatment, a defined matrix, the security fund, and the post-Durnell collapse of the litigation alternative.
A second likely issue is the opt-out process. After Durnell, the administrator received a wave of requests from class members who had opted out and wanted back in, which is why the fairness hearing was continued from Aug. 19. Bayer's CEO said on Nov. 3 that he expected the opt-out count to fall further through an administrative process after a final ruling. How the order treats revocations, and whether Monsanto exercises any termination right tied to excessive opt-outs, will be visible only in the order and later filings.
Does the Roundup settlement affect the federal Roundup MDL?
Indirectly, yes. Reuters reported that the settlement does not resolve lawsuits that have been consolidated in the federal proceeding, and the federal MDL continues before Judge Chhabria on its own track. But claimants have been leaving the MDL for months: the Judicial Panel on Multidistrict Litigation (JPML) counted 916 pending MDL 2741 actions on Nov. 2, 2026, down from 3,925 on Sept. 1, as claimants moved toward the class program.
The two courts are now working the same problem from opposite directions. On Nov. 16, Chhabria heard Monsanto's first supplemental motions arguing that Durnell also defeats negligence and Design Defect claims for some plaintiffs. If those motions succeed, the remaining federal and opt-out inventory faces a narrower set of viable theories; if they fail, Design Defect and negligent-testing claims remain a path for opt-outs, which affects both their settlement value and the price of any later individual deals Monsanto strikes outside the class.
What it means for claimants' counsel, defendants, funders and lienholders
Claimants' counsel with Roundup inventories. With the Roundup settlement approved, the operative date has shifted from approval to finality. Firms should expect registration and claim-documentation work to begin while an appeal remains possible, and should plan client communications around the 180-day post-appeal claims deadline rather than the approval date. For opt-out clients, the value of the claim now depends less on the class and more on what Chhabria and state trial courts do with post-Durnell Design Defect theories.
Corporate defendants and their insurers. If the approval survives appeal, King becomes the template for using a state-court Settlement Class, rather than the Texas Two-Step or a Section 524(g) Trust, to bind future claimants in a non-asbestos mass tort. Defendants facing latent-injury litigation, including PFAS, hair relaxer and other long-latency exposure dockets, will study the bankruptcy-risk finding closely, because it gave a trial court a solvency-based reason to prefer a binding class over individual litigation.
Litigation funders. Funded inventories held inside the class will be paid on the matrix over a multi-year schedule, which lengthens duration and compresses returns. Funded opt-out claims depend on the post-Durnell rulings. Both effects arrive while federal disclosure proposals for Third-Party Litigation Funding in MDLs and class actions remain pending in the Senate.
Health plans and Medical Lien holders. The dozen health plans among the objectors were protecting subrogation and reimbursement rights against tiered payments that may be modest for residential users. Lien resolution will run through the administrator, and the lower tiers leave less room for reimbursement after fees and costs.
The mass arbitration bar. The Roundup approval is a class-side answer to the aggregation problem that Mass Arbitration poses from the other direction. A Class Action Waiver pushes claimants into individual proceedings that then re-aggregate through Batching; a futures class pulls not-yet-injured people into a single proceeding before they have a claim. Both mechanisms try to price an entire claimant population at once, and the appellate fate of King will tell drafters and defense counsel how far a court will let that pricing reach.
Frequently asked questions
Was the Roundup settlement approved?
Yes, the Roundup settlement was approved. Judge Timothy Boyer of the Circuit Court of the City of St. Louis granted final approval to the $7.25 billion King v. Monsanto Co. class settlement on Nov. 20, 2026. The approval can still be appealed.
How much will I get from the Roundup settlement?
Payments range from about $10,000 to $165,000 across nine tiers based on exposure type, age at diagnosis and how aggressive the lymphoma is. Occupational users fall at the top of the range, and residential users are capped materially lower.
Does the Roundup settlement cover future cancer cases?
Yes. People exposed to Roundup in the United States before Feb. 17, 2026 who are diagnosed with non-Hodgkin lymphoma later can claim under the settlement within its claims window, and they gave up the right to sue separately unless they opted out by June 4, 2026.
How much do the lawyers get from the Roundup settlement?
The approved settlement includes $600 million in attorneys' fees, about 8.3 percent of the $7.25 billion maximum and less than the $675 million class counsel had requested. The fee comes out of the settlement, not on top of it.
When will Roundup settlement payments start?
Not until the approval order is final. Claims are due 180 days after any appeals are resolved; if no appeal is filed, the order would become final in late December 2026, and an appeal would likely push most payments into 2027 or beyond.
Can the Roundup settlement approval be appealed?
Yes. Class members who objected can appeal to the Missouri Court of Appeals, Eastern District, and objectors are expected to challenge the futures subclass under the reasoning of Amchem and Ortiz.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Roundup Settlement Final Approval Rests With Judge Boyer After a $7.25 Billion Fairness Hearing
Roundup settlement final approval is under submission: Judge Timothy Boyer reserved decision after the 14 September fairness hearing in St. Louis and directed proposed orders that week. Approval would bind roughly 65,000 pending claims and a nationwide futures subclass for sixteen years.
Torts Desk · 18 min

Roundup Settlement Before Christmas? Bayer CEO Says $7.25 Billion Approval 'Could Be Any Week Now'
Bayer expects the $7.25 billion Roundup settlement to win final approval before Christmas, CEO Bill Anderson said on Nov. 3, 2026, adding that many opt-outs now want back in. Approval would start the claims clock for roughly 65,000 cases, but objector appeals could still delay payment.
Torts Desk · 17 min

Roundup MDL Durnell Hearing: What Judge Chhabria Will Decide on November 16 and Which Claims Survive
Judge Vince Chhabria hears Monsanto's first post-Durnell dismissal motions in the Roundup MDL on Monday, November 16, 2026. The Roundup MDL Durnell hearing will show whether negligence and design defect claims outlive the Supreme Court's label ruling for the 916 federal cases left.
Torts Desk · 22 min